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Abstract
Purpose Gallium-68 is a metallic positron emitter with a
half-life of 68 min that is ideal for the in vivo use of small
molecules, such as [68Ga-DOTA,Tyr3]octreotide, in the
diagnostic imaging of somatostatin receptor-positive
tumours. In preclinical studies it has shown a striking
superiority over its 111In-labelled congener. The purpose of
this study was to evaluate whether third-generation somato-
statin-based, radiogallium-labelled peptides show the same
superiority.
Methods Peptides were synthesised on solid phase. The
receptor affinity was determined by in vitro receptor
autoradiography. The internalisation rate was studied in
AR4-2J and hsst-HEK-transfected cell lines. The pharma-
cokinetics was studied in a rat xenograft tumour model,
AR4-2J.
Results All peptides showed high affinities on hsst2, with
the highest affinity for the GaIII-complexed peptides. On
hsst3 the situation was reversed, with a trend towards lower
affinity of the GaIII peptides. A significantly increased
internalisation rate was found in sst2-expressing cells for all
67Ga-labelled peptides. Internalisation into HEK-sst3 was
usually faster for the 111In-labelled peptides. No internal-
isation was found into sst5. Biodistribution studies employ-
ing [67Ga-DOTA,1-Nal3]octreotide in comparison to
[111In-DOTA,1-Nal3]octreotide and [67Ga-DOTA,Tyr3]
octreotide showed a significantly higher and receptor-
mediated uptake of the two 67Ga-labelled peptides in the
tumour and somatostatin receptor-positive tissues. A patient
study illustrated the potential advantage of a broad receptor
subtype profile radiopeptide over a high-affinity sst2-
selective radiopeptide.
Conclusion This study demonstrates that 67/68Ga-DOTA-
octapeptides show distinctly better preclinical, pharmaco-
logical performances than the 111In-labelled peptides,
especially on sst2-expressing cells and the corresponding
animal models. They may be excellent candidates for
further development for clinical studies.
Keywords Somatostatin receptors . Gallium-68 .
Indium-111 . Radiopeptides . Imaging
Introduction
Peptide receptors with high overexpression on a variety of
human tumours are a focus of research in radiopharmacy
and nuclear oncology. The prototype is the somatostatin
receptor, which has been found to be overexpressed not
only on neuroendocrine tumours but also on renal cell
carcinoma, small cell lung cancer, breast cancer, prostate
cancer and malignant lymphoma [1]. Somatostatin ana-
logues have been radiolabelled with diagnostic radionu-
clides for imaging and tumour localisation as well as with
particle emitters for targeted radionuclide therapy. Labelling
has been performed with the γ-emitters 99mTc [2–4], 111In
[5, 6] and 67Ga [7], with the positron emitters 11C [8], 18F
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[9] and 64Cu [10], and with particle emitters such as 90Y
[11–14], 177Lu [15] and 213Bi [16]. [111In-DTPA]-octreo-
tide (Octreoscan) is the first registered radiopeptide and
currently the most sensitive method for staging of neuro-
endocrine tumours [17].
Currently, the metallic positron emitter 68Ga is of great
interest [18] because of its suitable radiophysical properties;
its positron yield is high, with 89% of all disintegrations.
Its half-life of 68 min matches the pharmacokinetics of
many peptides and other small molecules owing to a
fast blood clearance, quick diffusion and target local-
isation. In addition, and of major importance, is the fact
that it can be produced from a 68Ge/68Ga generator.
Especially attractive is the long half-life of 270.8 days
of the parent 68Ge, which allows use of the generator for
up to 1 year or even longer. A version of this generator is
now commercially available, and this is strongly motivat-
ing radiopharmacists to develop new radiogallium-based
radiopharmaceuticals.
We have been interested in designing peptide–chelator
conjugates for labelling with 67,68Ga, in particular those
based on somatostatin analogues. We used and compared
different chelators such as desferrioxamine [7], NOTAGA
(1,4,7-triazacyclononane,1-glutaric acid, 4,7-acetic acid)
[19] and DOTA (1,4,7,10-tetraazacyclododecane,1,4,7,10-
tetraacetic acid) [20, 21]. Interestingly, when DOTA was
coupled to the octapeptide [Tyr3]octreotide, the resulting
[67Ga-DOTA,Tyr3]octreotide ([67Ga-DOTA]-TOC) showed
not only about a fivefold increased affinity to the
somatostatin receptor subtype 2 (sst2) but also a 2.5-fold
increased tumour uptake compared with [111In-DOTA]-
TOC in a mouse xenograft model (AR4-2J). In addition,
the kidney uptake of [67Ga-DOTA]-TOC was distinctly
decreased compared with that of [111In-DOTA]-TOC or
[90Y-DOTA]-TOC [20, 21]. These very promising preclin-
ical data prompted several research groups to study [ 68Ga-
DOTA]-TOC in patients with somatostatin receptor-positive
tumours [22–27]. The Bad Berka group has almost 2 years’
experience employing 68Ga-DOTA-octapeptides in a vari-
ety of somatostatin receptor-positive tumour patients,
mainly gastroenteropancreatic (GEP) tumours [28, 29]. In
addition, first promising results have been reported [30, 31]
using [68Ga-DOTA,1-Nal3]octreotide ([68Ga-DOTA]-NOC)
receptor PET/CT in patients before and after peptide
receptor radionuclide therapy (PRRT). Furthermore,
[68Ga-DOTA,Tyr3,Thr8]octreotide ([68Ga-DOTA]-TATE)
was recently used in a patient with paraganglioma [32].
The main purpose of this work was to study the
hypothesis that the influence of radiogallium on pharma-
cological parameters such as receptor binding affinity, rate
of internalisation, tumour uptake etc. may be operative in
new DOTA-octapeptides (“third-generation somatostatin
analogues”). The latter differ from DOTA-TOC by virtue
of an improved somatostatin receptor subtype profile [33,
34]. In PET these new radiopharmaceuticals may have the
potential to target a wider range of tumours and to detect
more lesions in an individual patient. Therefore we
determined the affinity profiles with regard to hsst1–5 of
68/natGa-DOTA-octapeptides and compared them with those
of 111/natIn-DOTA-octapeptides (or in some cases 177/natLu-
and 90/natY-DOTA-octapeptides). We also studied the rate
of internalisation into sst2,3,5-expressing cell lines and the
biodistribution in a rat tumour model (AR4-2J). In addition,
we present first PET/CT studies using [68Ga-DOTA]-NOC
in comparison to [68Ga-DOTA]-TATE.
Materials and methods
All chemicals, including Fmoc(9-fluorenylmethoxycar-
bonyl)-protected amino acids, were obtained from com-
mercial sources and used without further purification.
Tritylchloride-resin was obtained from PepChem (Tübin-
gen, Germany). 67GaCl3 and
111InCl3 were from Mallinck-
rodt Medical (Petten, The Netherlands). The prochelator
DOTA(tBu)3 was synthesised according to Heppeler et al.
[20]. The reactive side chains of the amino acids were
masked with one of the following groups: Cys, acetamido-
methyl; Lys, t-butoxycarbonyl; Thr, t-butyl; Trp, t-butox-
ycarbonyl. Analytical reversed-phase high-performance
liquid chromatography (RP-HPLC) was carried out on a
Hewlett Packard 1050 HPLC system equipped with a
multiwavelength detector and a flow-through Berthold
LB506C1 γ-detector. Preparative HPLC was done on a
Bischof HPLC-system (Metrohm AG, Switzerland) with
HPLC-pumps 2250 and a Lambda 1010 UV-detector.
CC250/4 Nucleosil 120-3C18 columns from Macherey-
Nagel were used for analytical HPLC and a VP250/21
Nucleosil 200-5C15 column for preparative HPLC. The
gradient systems consisted of mixtures of acetonitrile and
water with 0.1% trifluoroacetic acid. Quantitative γ-count-
ing was performed on a COBRA 5003 γ-system well
counter from Packard Instrument Company (Switzerland).
Electrospray ionisation-mass spectrometry (ESI-MS)
was carried out with a Finnigan SSQ 7000 spectrometer
(Bremen, Germany).
Determination of lipophilicity
The octanol–water partition coefficients were determined
using the shake flask method. Both solvents (aqueous and
octanol) were presaturated with each other by shaking them
in contact for hours. To a solution of 100 nmol/l radio-
labelled peptide in 500 μl PBS (pH 7.4), 500 μl of octanol
was added (n=5). The mixtures were vigorously shaken for
1 h to reach equilibrium. After equilibration, the mixtures
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were centrifuged (10 min at 2,000 rpm) to achieve good
separation. The activity concentrations in 100-μl samples of
both the aqueous and the organic phase were measured in a
γ-counter. The partition coefficient (log D) was calculated
from the formula:
logD ¼ log 10
counts in octanol layer=counts in aqueous layerð Þ
Synthesis
The peptide–chelator conjugates were synthesised by
standard Fmoc-solid phase synthesis [34] on tritylchloride
resin (substitution 0.8 mmol/g) on a Rink Engineering
peptide synthesiser Switch 24 (RinkCombichem Technolo-
gies, Bubendorf, Switzerland) according to the general
procedure described previously [33], affording compounds
included in Fig. 1, which were characterised by ESI-MS
and RP-HPLC.
Formation of metal complexes for preclinical studies
The DOTA-octapeptides were complexed with InCl3
(anhydrous), Ga(NO3)3·5 H2O Lu(NO3)3·9 H2O and Y
(NO3)3·5 H2O as described by Wild et al. [33]. The ligands
were labelled with natural and radioactive indium or
gallium (111/natIn, 67/natGa) according to Ginj et al. [34]
and obtained in >99% radiochemical purity at specific
activities of >37 GBq/μmol peptide. For internalisation
experiments, the DOTA-peptides were labelled to a specific
activity of about 37 GBq/μmol peptide and then excess
InCl3 (anhydrous) or Ga(NO3)3·5 H2O was added, followed
by SepPak purification, to afford structurally characterised
homogeneous peptide ligands.
Synthesis of [68Ga-DOTA]-NOC for clinical study
For the 68Ga labelling, 30 mCi 68Ge/68Ge generators based
on TiO2 phase (Cyclotron Co., Obninsk, Russia) were used
to obtain 500–750 MBq of 68Ga. The generator eluate was
preconcentrated and purified from potential metallic impu-
rities on a micro-chromatography cation exchange column
(50W-X8, <400 mesh, Bio-Rad AG, Munich, Germany).
The activities were eluted with 98% acetone/0.05 mol/
l HCl (400 μl). This was added to 4 ml H2O containing
10 nmol DOTA-NOC and heated at 100°C for 10 min,
leading to a radiochemical yield >95%. The mixture was
subject to purification using Sep-Pak C18 cartridge, which
was washed with 5 ml H2O, followed by 0.5 ml of ethanol
diluted in 5 ml of isotonic saline. After sterility filtration,
quality control was performed using HPLC and thin-layer
chromatography. [68Ga-DOTA]-NOC was obtained with
specific activities of about 15 MBq/μg peptide.
Determination of somatostatin receptor affinity profiles
CHO-K1 and CCL39 cells stably expressing human sst1–5
(hsst1–5) were grown as described previously [35]. All
culture reagents were supplied by GIBCO/BRL and Life
Technologies (Grand Island, NY). Cell membrane pellets
were prepared and receptor autoradiography was performed
on pellet sections (mounted on microscope slides), as
described in detail previously [35]. For each of the tested
compounds, complete displacement experiments were
performed with the universal somatostatin radioligand
[125I]-[Leu8,D-Trp22,Trp25]-somatostatin-28 using increas-
ing concentrations of the MetalloIII-DOTA-peptide ranging
from 0.1 to 1,000 nmol/l. Somatostatin-28 was run in parallel
as control using the same increasing concentrations. IC50
values were calculated after quantification of the data using a
computer-assisted image processing system. Tissue standards
(autoradiographic [125I] microscales, Amersham, UK) con-
taining known amounts of isotopes, cross-calibrated to
tissue-equivalent ligand concentrations, were used for quan-
tification [35]. The concentrations of the peptide solutions
were measured by UV spectroscopy (ɛNOC-ATE, 280 nm=
9,855 cm−1 mol−1 dm3, ɛ BOC-ATE, 280 nm=7,570 cm
−1 mol−1
dm3, ɛ TOC, 280 nm>=6,849 cm
−1 mol−1 dm3, ɛNOC,280 nm>=
9,850 cm−1 mol−1 dm3).
Cell culture, radioligand internalisation and cellular
retention studies
The AR4-2J cell line was maintained by serial passage in
mono-layers in Dulbecco’s Modified Eagle’s Medium
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Fig. 1 Structural formulae of the peptides studied
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(DMEM), supplemented with 10% fetal bovine serum,
amino acids, vitamins and penicillin–streptomycin, in a
humidified 5% CO2 atmosphere at 37°C. Human embry-
onic kidney (HEK) 293 cells stably expressing rat sst2, sst3
and sst5 receptors (a gift from Dr. S. Schulz, Magdeburg,
Germany) [36] were grown in DMEM supplemented with
10% fetal bovine serum, penicillin–streptomycin and G418
(500 μg/ml) in a humidified 5% CO2 atmosphere at 37°C.
Cell numbers were counted under the microscope with a
Neubauer counting chamber. For all cell experiments, the
cells were seeded at a density of 0.8–1.1 million cells/well
in six-well plates and incubated overnight with internal-
isation buffer to obtain a good cell adherence. The loss of
cells during the internalisation experiments was below
10%. When different radiolabelled peptides were compared
in cell experiments, the same cell suspension-containing
plates were used. Furthermore, the internalisation rate was
linearly corrected to 1 million cells/well.
Medium was removed from the six-well plates and cells
were washed once with 2 ml of internalisation buffer
(DMEM, 1% fetal bovine serum, amino acids and vitamins,
pH 7.4). Furthermore, 1.5 ml internalisation buffer was
added to each well and incubated at 37°C for about 1 h.
Thereafter approximately 500,000 cpm or 0.02 MBq/well
67Ga/GaIII- and 111In/InIII-labelled peptides (2.5 pmol/well)
to a final concentration of 1.67 nmol/l were added to the
medium and the cells were incubated in triplicate at 37°C
for the indicated time periods. To determine non-specific
membrane binding and internalisation, cells were incubated
with the radioligand in the presence of 1 μmol/l [InIII-
DOTA]-NOC. Cellular uptake was stopped by removing
the medium from the cells and by washing twice with 1 ml
ice-cold PBS. An acid wash for 10 min with a glycine
buffer pH 2.8 on ice was also performed twice. This
procedure was performed to distinguish between mem-
brane-bound (acid-releasable) and internalised (acid-resis-
tant) radioligand. Finally, the cells were treated with 1 mol/l
NaOH. The culture medium, the receptor-bound and the
internalised fraction were measured radiometrically in a γ-
counter (Packard, Cobra II).
For cellular retention studies, HEK-sst2 cells (1 million)
were incubated with 2.5 pmol/well (1.67 nmol/l) [111In/
InIII]- or [67Ga/GaIII]-labelled DOTA-NOC, DOTA-BOC or
DOTA-TOC for 120 min, respectively, then the medium
was removed and the wells were washed twice with 1 ml
ice-cold PBS. In each experiment an acid wash for 10 min
on ice with a glycine buffer of pH 2.8 was performed twice
to remove the receptor-bound ligand. Cells were then
incubated again at 37°C with fresh internalisation buffer
(DMEM containing 1% fetal bovine serum, pH 7.4). After
different time points the external medium was removed for
quantification of radioactivity in a γ-counter and replaced
with fresh 37°C medium. The cells were solubilised in
1 mol/l NaOH and removed, and the internalised radioac-
tivity was quantified in a γ-counter. The externalised
fraction was expressed as percentage of the total internal-
ised amount per 1 million cells.
Biodistribution studies in tumour-bearing rats
Animals were kept, treated and cared for in compliance with
the guidelines of the Swiss regulations (approval #789).
Five-week-old male Lewis rats were implanted subcutane-
ously with 10–12 million AR4-2J cells freshly suspended in
sterile PBS. Fourteen days after inoculation, the rats showed
solid palpable tumour masses (tumour weight 0.4–0.7 g) and
were used for the experiments. Rats were injected under
ether anaesthesia with 2–3 MBq of 0.34 nmol (0.5 μg total
peptide mass) [111In-DOTA]-NOC, [67Ga-DOTA]-NOC or
[67Ga-DOTA]-TOC, in 0.05 ml NaCl solution 0.9% into the
femoral vein. At 4 h and 24 h after injection rats were
sacrificed under ether anaesthesia. Organs and blood were
collected and the radioactivity in these samples was
determined using a γ-counter.
In order to determine the non-specific uptake of the
radiopeptides, rats were injected with 50 μg [InIII-DOTA]-
NOC in 0.05 ml NaCl solution 0.9% as a co-injection with
the radioligand.
Patient study
Whole-body PET/CT scan was performed on a Siemens
biograph duo (Siemens, Germany). The 65-year-old male
patient was operated on owing to a neuroendocrine
pancreatic carcinoma (immunohistochemical staining posi-
tive for chromogranin and CD56) 6 months before the
PET/CT study by left pancreatectomy, splenectomy and
resection of a single liver metastasis in the left lobe
(segment SII). Postoperative treatment with octreotide
(Sandostatin LAR 20 mg/month) was started and stopped
4 weeks before the first PET/CT study.
Statistical methods
To compare differences between the radiopeptides, Stu-
dent’s t test was used. P values <0.05 were considered
significant.
Results
The peptides conjugated to DOTA presented in Fig. 1 were
synthesised by solid phase synthesis [33, 35]. Their
complexes were characterised by analytical HPLC and
ESI-MS. Radioligands were obtained at specific activities
of >37 GBq/μmol and a radiochemical purity of >97%.
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Receptor binding and affinity profiles
Table 1 summarises the IC50 values of the radiopeptides as
their InIII- and GaIII-complexed versions for the human
somatostatin receptors 1–5 (hsst1–hsst5), including data
published previously [35]. As a reference peptide, natural
somatostatin-28 is included. The values were obtained by
performing complete competition experiments with the
universal radioligand [125I][Leu8, D-Trp22, Tyr25]somato-
statin-28. In some cases the values for the LuIII- and/or
YIII-complexed peptides were included along with the
GaIII-peptides because all IC50 values, including those for
somatostatin-28, were determined in the same assay.
All metallopeptides bind with high affinity to hsst2 in
the low nanomolar range, with a significantly higher
binding affinity of the GaIII-complexed DOTA-peptides
compared to the other metallopeptides (InIII-, LuIII-, YIII-
complexed versions): differences range between two- and
eight-fold, depending on the assay. This holds for the
peptides included in Fig. 1 [octreotide, [Tyr3]octreotide
(TOC), [1-Nal3,Thr8]octreotide (NOC-ATE), [Tyr3,Thr8]
octreotide (TATE), [1-Nal3]octreotide (NOC) and [BzTh3]
octreotide (BOC)]. On hsst3 the IC50 values for the Ga
III-
DOTA-octapeptides were higher (affinity was lower) than
on hsst2. In addition and conversely to the hsst2 situation,
the binding affinity of GaIII-complexed peptides was lower
than that of the other metallopeptides. On hsst4 the affinity
is very low for most of the peptides, with a few exceptions.
Again, a tendency is seen for the GaIII-peptides to have a
somewhat higher affinity. On hsst5 all new metallopeptides
show good affinity, again with a tendency towards higher
affinity of the GaIII-complexed peptides with the exception
of [GaIII-DOTA]-NOC-ATE.
Internalisation studies in AR4-2J, HEK-sst2 and HEK-sst3
cells
Figure 2 shows a typical example of the time-dependent
internalisation of [68Ga-DOTA]-NOC and [111In-DOTA]-
NOC into the AR4-2J cell line. Table 2 summarises the
internalised percentage of several other octapeptides cou-
pled to DOTA and labelled with 67Ga and 111In at 4 h in the
three cell lines HEK-sst2, HEK-sst3 and AR4-2J. After 4 h,
23.9%±1.5% (2.5 pmol/106 cells) of [111In-DOTA]-NOC
was internalised into AR4-2J cells, while the corresponding
value for [67Ga-DOTA]-NOC was 41.1%±0.6%. In HEK-
sst2 cells the respective values were 25%±1.5% and 50%±
2%. Corresponding values for [111In-DOTA]-TOC and
[67Ga-DOTA]-TOC in AR4-2J cells were 11.5%±0.7%
and 16.5%±1.0%, respectively, whereas in the HEK-sst2
cells they were 16%±0.5% and 35%±1.0%, respectively.
The specific uptake in HEK-sst3 cells was lower for all
radiopeptides. For this receptor the 111In-labelled peptides
internalised significantly better than the 67Ga-labelled ones,
with the exception of [111In-DOTA]-NOC/[67Ga-DOTA]-
NOC, which internalised at an equal rate. No internalisation
Table 1 Affinity profiles of DOTA-octapeptides (IC50) for hsst1–5 receptors
Compound hsst1 hsst2 hsst3 hsst4 hsst5
Somatostatin-28 3.8±0.3 (10) 2.5±0.3 (11) 5.7±0.6 (10) 4.2±0.3 (11) 3.7±0.4 (11)
Ga-DOTA-NOC >10,000 (3) 1.9±0.4 (3) 40.0±5.8 (3) 260±74 (3) 7.2±1.6 (3)
In-DOTA-NOC >10,000 (3) 2.9±0.1 (3)b 8.0±2.0 (3)b 227±18 (3) 11.2±3.5 (3)
Lu-DOTA-NOC >10,000 (3) 3.4±0.4 (3)b 12.0±3.3 (3)b 747±47 (3)b 14.0±3.5 (3)b
In-DOTA-BOC >1,000 (2) 4.4±0.4 (3)b 6.8±0.3 (3)b ND 10.5±1.5 (3)b
Lu-DOTA-BOC >1,000 (2) 4.0±0.4 (3)b 6.3±0.2 (3)b 591±88 (2) 6.5±0.1 (3)b
Ga-DOTA-BOC 700±300 (2) 1.7±0.2(3) 10.5±0.5 (3) ND 4.4±1.2 (3)
Y-DOTA-NOC-ATE >1,000 (2) 4.2±2.0 (3) 47±1 (3) ND 12±1 (3)b
Lu-DOTA-NOC-ATE >1,000 (2) 3.6±0.3 (3)b 30±2 (3) ND 15±1 (3)b
Ga-DOTA-NOC-ATE >1,000 (2) 2.6±0.3 (3) 113±80 (2) 53±30 (2) 25±4 (3)
Y-DOTA-BOC-ATE >1,000 (2) 2.9±0.3 (3)b 23±1 (3) ND 7.8±2.0 (3)
Ga-DOTA-BOC-ATE >1,000 (2) 2.0±0.2 (3) 33±23 (2) 35±24 (2) 19.5±13.0 (2)
Somatostatin-28a 5.2±0.3 (19) 2.7±0.3 (19) 7.7±0.9 (15) 5.6±0.4 (19) 4.0±0.3 (19)
Ga-DOTA-TOCa >10,000 2.5±0.5 613±140 >1,000 73±21
Y-DOTA-TOCa >10,000 11.0±1.7b 389±135 >10,000 114±29
Ga-DOTA-OCa >10,000 7.3±1.9 120±45 >1,000 60±14
Y-DOTA-OCa >10,000 20±2b 27±8b >10,000 57±22
Ga-DOTA-TATEa >10,000 0.20±0.04 >1,000 300±140 377±18
Y-DOTA-TATEa >10,000 1.6±0.4b >1,000 523±239 187±50b
IC50 values are in nmol/l (mean±SEM). Number of independent studies is given in parentheses. Somatostatin-28 was used as control
ND not determined
a Data including the control peptide somatostatin-28 are from Reubi et al. [35]
b Significant difference (p<0.05) of the GaIII -complexed peptides vs the other metallopeptides
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was found for [111In-DOTA]-TOC or [67Ga-DOTA]-TOC in
HEK-sst3 cells.
Efflux was studied with HEK-sst2 cells, which were
allowed to internalise the radioligands for 2 h. The
percentage of externalised radiopeptide at 4 h was 30±
2% for [67Ga-DOTA]-NOC, 30±5% for [67Ga-DOTA]-
TOC, 25±3% for [111In-DOTA]-NOC and 25±4% for
[111In-DOTA]-BOC.
Biodistribution in AR4-2J tumour-bearing rats
The 4-h and 24-h uptake values of [67Ga-DOTA]-NOC and
[111In-DOTA]-NOC in Lewis rats bearing the AR4-2J rat
pancreatic tumour in sst-positive organs such as the
pancreas, adrenals, pituitary and stomach, in the tumour
and in other tissues are shown in Table 3, in comparison
with the values for [67Ga-DOTA]-TOC. The three radio-
peptides showed rapid blood clearance with very low levels
of radioactivity remaining in blood at 4 h: 0.02%±0.00%
IA/g for [111In-DOTA]-NOC (% IA/g is the percentage of
injected activity per gram tissue), 0.03%±0.01% IA/g for
[67Ga-DOTA]-NOC and 0.07%±0.006% IA/g for [67Ga-
DOTA]-TOC. At 24 h the blood activity was down to
0.01% IA/g for all three radiopeptides. The uptake in the
tumour was high at 4 h and receptor mediated, as shown by
a separate blocking experiment: co-injection of 100 μg
DOTA-NOC resulted in >92% blockage of tumour uptake.
[67Ga-DOTA]-NOC accumulated specifically and signifi-
cantly higher in the tumour than did [111In-DOTA]-NOC at
4 h and 24 h. Higher uptake of [67Ga-DOTA]-NOC was
also found in most other somatostatin receptor-positive
organs such as the adrenals, the bowel and the pituitary.
The specificity of uptake in these organs was again
demonstrated by blocking of the organs with excess cold
peptide. Co-injection of 100 μg DOTA-NOC efficiently
blocked (by >93%) the uptake in all of these organs except
the bowel, where the blocking was by 81%. No blocking
was found for the liver, the kidneys or the spleen.
The liver uptake of [67Ga-DOTA]-NOC was relatively
high (0.95%±0.09% IA/g at 4 h) and significantly higher
than that of [111In-DOTA]-NOC (0.21%±0.04% IA/g).
The lowest liver uptake at 4 h was found for [67Ga-DOTA]-
TOC (0.09%±0.01% IA/g). The kidney uptake was lowest
for [67Ga-DOTA]-NOC (0.95%±0.18% IA/g at 4 h;
0.79%±0.06% IA/g at 24 h), followed by [111In-DOTA]-
NOC (1.37%±0.21% IA/g at 4 h, 1.27%±0.1% IA/g at
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Fig. 2 Comparison of the rate of internalisation of [111In-DOTA]-
NOC (Δ) and [67Ga-DOTA]-NOC (∎) into AR4-2J cells. Values and
standard deviations are the result of three independent experiments
with triplicates in each experiment and are expressed as specific
internalisation (percentage of activity added to 1 million cells at
1.67 nmol/l concentration, 37°C)
Table 2 Internalisation of [67Ga]- or [111In]-labelled peptides into AR4-2J, HEK-sst2 and HEK-sst3 cells after 4-h incubation at 37°Ca
Radiopeptide % internalised in
AR4-2J cells
% internalised in
HEK-sst2 cells
% internalised in
HEK-sst3 cells
[67Ga-DOTA]-TOC 16.50±1.0 35.0±1.0 <0.1
[111In-DOTA]-TOC 11.50±0.7 16.0±0.5 <0.1
[67Ga-DOTA]-TATE 33.7±1.3 45.4±0.7 <0.6
[111In-DOTA]-TATE 21.0±2.3b ND ND
[67Ga-DOTA]-NOC 41.1±0.6 50.0±2.0 14.3±0.5
[111In-DOTA]-NOC 23.9±1.5 25.0±1.5 14.0±1.0
[67Ga-DOTA]-NOC-ATE 28.3±1.6 50.0±3.0 2.4±0.15
[111In-DOTA]-NOC-ATE 25.1±1.3 29.0±2.0 13.6±0.8
[67Ga-DOTA]-BOC 26.5±1.3 55.9±1.2 18.5±1.1
[111In-DOTA]-BOC 17.2±1.9 38.7±0.9 24.3±0.9
[67Ga-DOTA]-BOC-ATE 23.7±0.6 56.0±0.5 4.1±0.5
[111In-DOTA]-BOC-ATE 17.8±0.8 51.1±0.95 20.1±0.5
ND not determined
a Specific internalisation (% activity added to 1 million cells at 1.67 nmol/l concentration) and result of three independent experiments with
triplicates in each experiment; Student’s t test yielded significant differences (p values <0.02) for the comparison of all [67 Ga-DOTA]- vs [111 In-
DOTA]-peptides on sst2 (AR4-2J and HEK-sst2) and HEK-sst3 with the exception of [67 Ga-DOTA]-NOC vs [ 111 In-DOTA]-NOC in HEK-sst3
b From ref. [4].
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24 h) and [67Ga-DOTA]-TOC (1.55%±0.25% IA/g at 4 h;
1.37%±0.18% IA/g at 24 h).
Owing to the fast blood clearance, the tumour-to-blood
ratio was very high for all three radiopeptides. At 4 h it was
142 for [67Ga-DOTA]-NOC, 148 for [111In-DOTA]-NOC
and 68 for [67Ga-DOTA]-TOC. The ratios increased to 402,
265 and 270, respectively, at 24 h. The tumour-to-kidney
ratio at 4 h was 4.5 for [67Ga-DOTA]-NOC, 2.2 for [111In-
DOTA]-NOC and 3.1 for [67Ga-DOTA]-TOC. The ratio
increased somewhat for [67Ga-DOTA]-NOC at 24 h (to 5.1)
but decreased for the two other peptides. Whereas the
tumour-to-liver ratio was very high for [67Ga-DOTA]-TOC
(53.2 at 4 h and 27 at 24 h), it was 14.1 at 4 h and 17.7 at
24 h, respectively, for [111In-DOTA]-NOC and 4.5 at 4 h
and 4.3 at 24 h for [67Ga-DOTA]-NOC.
A clinical case report comparing [68Ga-DOTA]-NOC
with [68Ga-DOTA]-TATE
In Fig. 3 an example is given of a patient with a
neuroendocrine pancreatic carcinoma. The patient was
scanned with [68Ga-DOTA]-NOC (Fig. 3a), [68Ga-
DOTA]-TATE (Fig. 3b) and [18F]fluorodeoxyglucose
(FDG) (Fig. 3d). Eighty-five MBq [68Ga-DOTA]-NOC
was injected. The scan, performed at 140 min p.i., revealed
very intense uptake (SUVmax 152) in a left retrocrural
lymph node metastasis (Fig. 3a) as well as in a para-
pancreatic lymph node (SUV 9.2) and in a very small
lesion near the processus uncinatus of the pancreas (SUV
6.8). In addition, a small (10 mm) liver metastasis in the
right inferior liver segment (S VI) was detected (SUV 11.6)
(Fig. 3c), which had also been described in an MRI study.
The second PET/CT was performed 3 weeks later after
i.v. injection of 130 MBq of [68Ga-DOTA]-TATE, starting
the acquisition 85 min p.i. Again, very high uptake
(SUVmax 103) was seen in the retrocrural metastasis
(Fig. 3b), but no other lesions were detectable (Fig. 3c).
There was no increased glucose metabolism (normal
[18F]FDG PET/CT) in any of the lesions shown by the
receptor PET/CT studies (Fig. 3d).
Discussion
The use of 68Ga in nuclear oncology is becoming of
increasing interest as it is a generator-produced, easily
available positron emitter. 68Ga has a physical half-life of
68 min, which is compatible with the pharmacokinetics of
most radiopharmaceuticals of low molecular weight such
as antibody fragments, peptides, aptamers, oligonucleo-
tides, etc. [37, 38]. 68Ga decays to 89% by positron
emission and to 11% via electron capture. The parent
isotope 68Ge has a very long half-life of 270.8 days, which
allows routine manufacture and shipment, while the
Table 3 Biodistribution in AR4-2J tumour-bearing rats and tissue ratios at 4 h and 24 h p.i. of [111In-DOTA]-NOC, [67Ga-DOTA]-NOC and
[67Ga-DOTA]-TOC
Site [111In-DOTA]-NOC [67Ga-DOTA]-NOC [67Ga-DOTA]-TOC
4 h 4 h blockeda 24 h 4 h 4 h blockeda 24 h 4 h 4 h blockeda 24 h
Blood 0.02±0.00 0.03±0.01 0.01±0.00 0.03±0.01 0.02±0.01 0.01±0.00 0.07±0.006** 0.06±0.00 0.01±0.005
Tumour 2.96±0.48 0.24±0.01 2.65±0.41 4.24±0.37* 0.30±0.00 4.02±0.32* 4.6±1.18** 0.28±0.00 2.70±0.17**
Kidneys 1.37±0.21 1.83±0.02 1.27±0.10 0.95±0.18 0.91±0.13 0.79±0.06* 1.55±0.25** 1.64±0.018 1.37±0.18**
Adrenals 8.24±1.16 0.55±0.07 1.02±0.17 14.14±1.46* 0.32±0.05 6.46±0.60* 10.90±0.35** 0.16±0.00 6.35±0.64
Pancreas 7.94±0.71 0.16±0.03 4.04±0.29 7.13±0.63 0.34±0.04 3.15±0.62 13.32±0.78** 0.299±0.00 6.14±1.04**
Spleen 0.09±0.01 0.09±0.03 0.09±0.02 0.12±0.02 0.13±0.03 0.13±0.04 0.08±0.01** 0.088±0.00 0.14±0.11
Stomach 1.64±0.19 0.05±0.02 1.08±0.11 1.99±0.23 0.07±0.01 0.91±0.05 1.76±0.11 0.06±0.00 0.912± 0.22
Bowel 0.36±0.26 0.07±0.01 0.27±0.15 0.26±0.04 0.04±0.01 0.79±0.06* 0.23±0.02 0.04±0.00 0.18±0.006**
Liver 0.21±0.04 0.22±0.02 0.15±0.01 0.95±0.09* 1.04±0.11 0.93±0.05* 0.09±0.01** 0.12±0.00 0.10±0.07**
Lung 0.06±0.01 0.05±0.001 0.05±0.02 0.13±0.02* 0.12±0.01 0.13±0.03* 0.09±0.01** 0.08±0.00 0.11±0.10
Heart 0.01±0.00 0.02±0.004 0.01±0.00 0.05±0.00 0.04±0.01 0.04±0.01* 0.03±0.01** 0.02±0.00 0.015±0.003**
Pituitary 6.21±0.73 0.18±0.05 5.44±0.79 11.08±1.41* 0.20±0.03 6.00±0.66 10.33±1.90 0.21±0.00 6.65±0.06
Tumour to tissue ratios
Tumour/blood 148.0 265.0 142.0 402.0 68.5 270.0
Tumour/kidney 2.2 2.1 4.5 5.1 3.1 1.97
Tumour/liver 14.1 17.7 4.5 4.3 53.2 27.0
Values are the mean of % IA/g ±SD for groups of three or four animals
IA injected activity
*,** Significant differences (p<0.05): *between [111 In-DOTA]-NOC and [67 Ga-DOTA]-NOC; **between [67 Ga-DOTA]-NOC and
[67 Ga-DOTA]-TOC
a Blocked with 0.1 mg DOTA-NOC as a co-injection with the radiopeptide
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chemical properties of Ge(IV) and Ga(III) are sufficiently
different to allow several different methods of efficient
separation.
A particularly fascinating group of 68Ga-based radio-
pharmaceuticals are chelator-modified regulatory peptides
that, owing to their small size, have ideal pharmacokinetics
compatible with the short-lived 68Ga. Particularly somato-
statin derivatives such as [natGa-DOTA]-TOC and [natGa-
DOTA]-TATE show outstanding binding affinity to sst2
that is a factor of 4–8 higher compared with the
corresponding yttrium or indium derivatives [5, 20, 35].
The higher binding affinity resulted in significantly higher
tumour uptake in a tumour-bearing mouse model [20, 21].
These positive preclinical results have prompted several
Fig. 3 Comparison between
68Ga-DOTA-NOC and 68Ga-
DOTA-TATE in the same
patient (with a metastatic neu-
roendocrine pancreatic tumour),
along with an [18F]FDG PET/
CT scan. The first whole-body
PET/CT study (Siemens biog-
raph duo) was performed after
i.v. injection of 85 MBq 68Ga-
DOTA-NOC and revealed very
intense uptake (SUVmax of 152)
in a left retrocrural lymph node
metastasis (A. In addition, a
liver metastasis (about 10 mm in
diameter on MRI) in the right
inferior liver segment (S VI)
(SUV 11.6, C: a) and a very
small parapancreatic lymph
node metastasis (C: c) were
detected. The second PET/CT
scan was performed 3 weeks
later after i.v. injection of
130 MBq of 68Ga-DOTA-TATE.
Again, very high uptake
(SUVmax 103) was seen in the
retrocrural metastasis (B), but
no other lesions were detectable
(C: b,d). There was no in-
creased glucose metabolism
(normal 18F-FDG PET/CT, D)
in any of the lesions shown by
receptor PET/CT
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clinical groups to use [68Ga-DOTA]-TOC and [68Ga-
DOTA]-TATE in patient studies [22–27, 32].
We have recently reported that [111In-DOTA]-NOC may
be a promising candidate for somatostatin receptor-positive
tumour targeting because it recognises three somatostatin
receptor subtypes with high affinity and may therefore
target a broader range of tumours. Indeed, some preliminary
results suggest that this new radiopeptide, if labelled with
68Ga, locates more metastases than the second-generation
radiopeptides [30, 39–41], indicating that these new
peptides are also pharmacologically superior compared
with their 111In congeners. We designed a study to support
these early clinical observations with firm preclinical
pharmacological data using the 68Ga congener, 67Ga.
A general trend was seen in regard to the binding affinity
and the affinity profile of the GaIII vs MIII-DOTA-peptides
Fig. 3 (continued)
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(MIII = InIII, LuIII, YIII). On hsst2, the binding affinities
were significantly higher for the gallium-labelled peptides
than for the MIII-DOTA-peptides (p<0.0125). The differ-
ence was not significant for [GaIII-DOTA]-NOC-ATE vs
[YIII-DOTA]-NOC-ATE (p>=0.124) but otherwise the
GaIII derivatives had a two- to eightfold higher affinity.
On hsst3 there was a tendency in the opposite direction:
the affinities of the GaIII-complexed peptides were two- to
fivefold lower. On hsst5 no clear tendency was obvious.
None of the peptides has affinity to sst1 but surprisingly
some emerging hsst4 affinity can be seen, especially when
complexed with GaIII. We do not yet know which structural
features are responsible for the latter.
A more striking advantage of the 67Ga-DOTA-peptides
becomes evident upon studying the rate of internalisation
into different cell lines. In sst2-expressing cells all 67Ga-
labelled peptides showed high and specific internalisation
with a significantly higher rate compared with the 111In
congeners. The difference between the two radionuclides
became more striking when the internalisation was studied
in HEK-sst2 cells, which express a higher number of
receptors compared with AR4-2J cells.
In an earlier paper, Froidevaux et al. found no
statistically significant difference between [67Ga-DOTA]-
TOC and [111In-DOTA]-TOC in AR4-2J cells [21]. The
present data, however, showed a significant difference
between the two radiopeptides. The internalisation into
HEK-sst3 was comparatively low with no uptake of
[67Ga/111In-DOTA]-TOC, as expected, and paralleling the
very low binding affinity of these two peptides to sst3. In
contrast to the sst2 data, the general tendency was for the
111In-labelled peptides to show more efficient internal-
isation into sst3, with the exception of [67Ga-DOTA]- and
111In-DOTA]-NOC, which internalised at an equal rate, not
corresponding to the fivefold difference in binding affinity.
None of the radiopeptides internalises into sst5, which
most likely is an intrinsic property of this receptor [42].
These in vitro pharmacological data indicate that [67Ga-
DOTA]-BOC is the most promising radiopeptide to
develop. However, as it showed some instability during
labelling, we decided to study [67Ga-DOTA]-NOC in our
tumour model. The analysis of the biodistribution at 4 and
24 h showed a significantly higher tumour uptake of [67Ga-
DOTA]-NOC compared with [111In-DOTA]-NOC. We
hypothesise that the more rapid internalisation kinetics
measured in vitro contributes to the increased in vivo
uptake. We recently found that in a group of six
somatostatin-based octapeptides labelled with 99mTc and
111In, a good correlation indeed existed between tumour
and pancreas uptake in vivo and the rate of internalisation
into the AR4-2J cell line in vitro [4]. The uptake in other
somatostatin receptor-positive tissues, such as the adrenals,
the stomach and the bowel, follows this trend.
The potential of an imaging probe depends, among other
parameters, on the target-to-non-target ratios, especially the
tumour-to-blood ratio. All three radiopeptides showed a
very high tumour-to-blood ratio, [67Ga-DOTA]-NOC hav-
ing the highest among them. In addition, the tumour-to-
kidney ratio of 4.5 at 4 h and 5.1 at 24 h is, to the best of
our knowledge, the highest of any radiometal-labelled
peptide reported so far. On the other hand, the tumour-to-
liver ratio was clearly lowest for [67Ga-DOTA]-NOC. This
result was due to the almost fivefold higher liver uptake of
[67Ga-DOTA]-NOC compared with that of [111In-DOTA]-
NOC, which is somewhat surprising considering the much
lower log D value (higher hydrophilicity; see Table 4) of
[67Ga-DOTA]-NOC compared with [111In-DOTA]-NOC. It
is currently unclear whether active mechanisms including
organic anion transporters are involved in the increased
liver uptake.
An interesting finding from this study is that the
radiometal indeed influences the pharmacological proper-
ties of the radiopeptides; this earlier finding [21, 35] can be
extended to the new generation of somatostatin-based
radiopeptides. Labelling with 67/68Ga results in peptides
that are superior to those labelled with 111In, 90Y or 177Lu.
We have explained this difference by a difference in the
coordination number and geometry of the various radio-
metal complexes [20]. The model peptide GaIII-DOTA-D-
PheNH2 showed a cis-pseudo-octahedral geometry without
the coordination of the amide linkage and the corre-
sponding trans carboxy methyl group, whereas the YIII
complex is octacoordinate including the amide carboxy
oxygen and the carboxymethyl group. The complex
geometry is a somewhat distorted square antiprism [20].
The non-involved amide linkage of the GaIII complex
consequently offers more flexibility, the free arm acting as a
spacer between peptide and chelate. This may lead to the
higher binding affinity on hsst2 whereas the free carboxyl-
ate group may favour kidney excretion.
In summary, these data suggest that most, if not all,
68Ga-labelled second- and third-generation somatostatin-
based radiopeptides show superior properties in imaging
somatostatin receptor-positive tumours compared with first-
generation somatostatin-based radiopeptides. This is due to
superior pharmacological properties on hsst2, which is the
most densely and frequently expressed receptor subtype.
Despite some loss in hsst3 and hsst5 affinity, the radio-
Table 4 Log D at pH=7.4 of radiolabelled conjugates
Compound name Log D (pH=7.4)
[67Ga-DOTA]-NOC −2.88±0.12
[111In-DOTA]-NOC −2.06±0.20
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gallium-labelled peptides still show a broad hsst profile.
Given the higher sensitivity of the PET technique, [68Ga-
DOTA]-NOC and [68Ga-DOTA]-BOC should also be
further developed into new PET tracers for extended
clinical studies.
The intra-individual comparison of [68Ga-DOTA]-NOC
and [68Ga-DOTA]-TATE (Fig. 3a–c) in a patient with
metastases of a neuroendocrine pancreatic carcinoma
demonstrated that the broader somatostatin receptor sub-
type profile of [68Ga-DOTA]-NOC (sst2, 3 and 5 affinity)
and internalisation may be of clinical relevance as a
significantly higher uptake of this radiopeptide was found
(SUVmax 152) compared with the high-affinity but sst2-
selective radiopeptide [68Ga-DOTA]-TATE (SUVmax 103).
In addition, very small lesions were detected when using
[68Ga-DOTA]-NOC as compared to [68Ga-DOTA]-TATE.
Along with the 68Ge/68Ga generator, these tracers may be
very cost effective, sensitive and readily available imaging
agents. Furthermore, they cause low radiation doses to
patients compared with existing tracers and their 111In-
labelled congeners [31]. Along with 64Cu-labelled radio-
pharmaceuticals [43–45], 68Ga-labelled compounds are a
fast-growing area of research which benefits from the
availability of a commercial generator.
Acknowledgements P. Antunes acknowledges the PhD Fellowship
of the Fundação para a Ciência e Tecnologia (Ref. SFRH/BD/3136/
2000). In addition, P. Antunes, M. Ginj, M. Walter and H. Maecke
acknowledge the support from the Swiss National Science Foundation
project No. 3100A0-100390, BBW project No C00.0091, and the
network of excellence, European Molecular Imaging Laboratories
(EMIL). The support provided by Novartis Pharma in respect of ESI-
MS analysis is gratefully acknowledged. We thank Dr. S. Schulz for
the sst3-transfected human embryonic kidney 293 cells. The authors
thank K. Hinni and S. Tschumi for biological technical assistance.
This work was performed within the COST B12 Action.
References
1. Reubi JC. Peptide receptors as molecular targets for cancer
diagnosis and therapy. Endocr Rev 2003;24:389–427.
2. Maina T, Nock B, Nikolopoulou A, Sotiriou P, Loudos G, Maintas
D, et al. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate
analogue for the detection of somatostatin receptor-positive
tumours: synthesis and preclinical results. Eur J Nucl Med Mol
Imaging 2002;29:742–53.
3. Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E,
Riccabona G, Moncayo R. 99mTc-EDDA/HYNIC-TOC: a new
99mTc-labelled radiopharmaceutical for imaging somatostatin
receptor-positive tumours; first clinical results and intra-patient
comparison with 111In-labelled octreotide derivatives. Eur J Nucl
Med 2000;27:1318–25.
4. Storch D, Behe M, Walter MA, Chen J, Powell P, Mikolajczak R,
et al. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives
compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-
DTPA0]octreotide: does tumor or pancreas uptake correlate with
the rate of internalization? J Nucl Med 2005;46:1561–9.
5. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der
Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111
labelling, receptor binding and biodistribution of [DOTA0,D-
Phe1,Tyr3]octreotide, a promising somatostatin analogue for
radionuclide therapy. Eur J Nucl Med 1997;24:368–71.
6. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA,
Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy
with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotter-
dam experience with more than 1000 patients. Eur J Nucl Med
1993;20:716–31.
7. Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich
R, et al. Gallium-67/gallium-68-[DFO]-octreotide—a potential
radiopharmaceutical for PET imaging of somatostatin receptor-
positive tumors: synthesis and radiolabeling in vitro and prelim-
inary in vivo studies. J Nucl Med 1994;35:317–25.
8. Henriksen G, Schottelius M, Poethko T, Hauser A, Wolf I,
Schwaiger M, et al. Proof of principle for the use of 11C-labelled
peptides in tumour diagnosis with PET. Eur J Nucl Med Mol
Imaging 2004;31:1653–7.
9. Wester H-J, Schottelius M, Scheidhauer K, Meisetschläger G,
Herz M, Rau F, et al. PET imaging of somatostatin receptors:
design, synthesis and preclinical evaluation of a novel 18F-
labelled, carbohydrated analogue of octreotide. Eur J Nucl Med
Mol Imaging 2002;30:117–22.
10. Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S,
et al. Preparation and biological evaluation of copper-64-labeled
Tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin
Cancer Res 2004;10:8674–82.
11. Waldherr C, Pless M, Maecke H, Schumacher T, Crazzolara A,
Nitzsche E, et al. Tumor response and clincical benefit in
neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl
Med 2002;43:610–6.
12. Otte A, Mueller-Brand J, Dellas S, Nitzsche E, Herrmann R,
Maecke H. Yttrium-90-labelled somatostatin-analogue for cancer
treatment. Lancet 1998;351:417–8.
13. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB,
Pauwels S, Kvols LK, et al. Overview of results of peptide
receptor radionuclide therapy with 3 radiolabeled somatostatin
analogs. J Nucl Med 2005;46:62S–66S.
14. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca
P, et al. Receptor-mediated radionuclide therapy with 90Y-
DOTATOC in association with amino acid infusion: a phase I
study. Eur J Nucl Med 2003;30:207–16.
15. de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M,
van Gameren A, et al. [177Lu-DOTA0,Tyr3]octreotate for somato-
statin receptor-targeted radionuclide therapy. Int J Cancer
2001;92:628–33.
16. Norenberg JP, Krenning BJ, Konings IR, Kusewitt DF, Nayak TK,
Anderson TL, et al. 213Bi-[DOTA0, Tyr3]octreotide peptide
receptor radionuclide therapy of pancreatic tumors in a preclinical
animal model. Clin Cancer Res 2006;12:897–903.
17. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent
advances in molecular pathogenesis, localization, and treatment.
Curr Opin Oncol 2000;12:368–77.
18. Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in
tumor imaging. J Nucl Med 2005;46:172S–8S.
19. Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC,
Wenger S, et al. NODAGATOC, a new chelator-coupled somato-
statin analogue labeled with [67/68Ga] and [111In] for SPECT, PET,
and targeted therapeutic applications of somatostatin receptor
(hsst2) expressing tumors. Bioconjug Chem 2002;13:530–41.
20. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M,
Powell P, et al. Radiometal-labelled macrocyclic chelator-
derivatised somatostatin analogue with superb tumour-targeting
properties and potential for receptor-mediated internal radiother-
apy. Chemistry A European Journal 1999;5:1016–23.
992 Eur J Nucl Med Mol Imaging (2007) 34:982–993
21. Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A,
Schmitt JS, et al. Neuroendocrine tumor targeting: study of novel
gallium-labeled somatostatin radiopeptides in a rat pancreatic
tumor model. Int J Cancer 2002;98:930–7.
22. Hofmann M, Maecke H, Börner A, Weckesser E, Schöffski P, Oei
M, et al. Biokinetics and imaging with the somatostatin receptor
PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl
Med 2001;28:1751–7.
23. Kowalski J, Henze M, Schuhmacher J, Maecke HR, Hofmann M,
Haberkorn U. Evaluation of positron emission tomography
imaging using [68Ga]-DOTA-D Phe1-Tyr3-octreotide in compari-
son to [111In]-DTPAOC SPECT. First results in patients with
neuroendocrine tumors. Mol Imaging Biol 2003;5:42–8.
24. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S,
Schuhmacher J, Strauss LG, Doll J, et al. Characterization of
68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with
meningiomas. J Nucl Med 2005;46:763–9.
25. Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss
LG, Maecke HR, Eisenhut M, et al. Exceptional increase in
somatostatin receptor expression in pancreatic neuroendocrine
tumour, visualised with 68Ga-DOTATOC PET. Eur J Nucl Med
Mol Imaging 2004;31:466.
26. Henze M, Schumacher T, Hipp P, Kowalski J, Becker D, Doll J, et
al. PET imaging of somatostatin receptors using [68Ga]DOTA-D-
Phe1-Tyr3-octreotide: first results in patients with meningiomas.
J Nucl Med 2001;42:1053–6.
27. Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F,
Koukouraki S, Macke HR, et al. Quantitative assessment of
SSTR2 expression in patients with non-small cell lung cancer
using 68Ga-DOTATOC PET and comparison with 18F-FDG PET.
Eur J Nucl Med Mol Imaging 2006;33:823–30.
28. Baum R, Niesen A, Leonhardi J, Wortmann R, Mueller D, Roesch
F. Receptor PET/CT imaging of neuroendocrine tumours using
the Ga-68 labelled, high affinity somatostatin analogue DOTA-1-
Nal3 octreotide (DOTA-NOC): clinical results in 327 patients.
Eur J Nucl Med Mol Imaging 2005;32 Suppl 1:S54–5.
29. Roesch F, Zhernosekov K, Filosofov D, Jahn M, Jennewein M,
Baum R, et al. Processing of Ge-68/Ga-68 generator eluates for
labeling of biomolecules via bifunctional chelators. J Nucl Med
2006;47 Suppl 1:162P.
30. Baum R, Schmücking M, Wortmann R, Müller M, Zhernosekov
K, Rösch F. Receptor PET/CT using the Ga-68 labelled
somatostatin analog DOTA-1-Nal3-octreotide (DOTA-NOC): clin-
ical experience in 140 patients. Nuklearmedizin 2005;44:A57.
31. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine
tumors. Semin Nucl Med 2006;36:228–47.
32. Win Z, Rahman L, Murrell J, Todd J, Al-Nahhas A. The possible
role of 68Ga-DOTATATE PET in malignant abdominal para-
ganglioma. Eur J Nucl Med Mol Imaging 2006;33:506.
33. Wild D, Schmitt JS, Ginj M, Maecke HR, Bernard BF, Krenning
E, et al. DOTA-NOC, a high-affinity ligand of somatostatin
receptor subtypes 2, 3 and 5 for labelling with various radio-
metals. Eur J Nucl Med Mol Imaging 2003;30:1338–47.
34. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke
HR. Preclinical evaluation of new and highly potent analogues of
octreotide for predictive imaging and targeted radiotherapy. Clin
Cancer Res 2005;11:1136–45.
35. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt
JS, et al. Affinity profiles for human somatostatin receptor
subtypes SST1–SST5 of somatostatin radiotracers selected for
scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:
273–82.
36. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Hollt V,
Schulz S. Differential β-arrestin trafficking and endosomal sorting
of somatostatin receptor subtypes. J Biol Chem 2004;279:21374–
82.
37. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson
SM. Imaging the pharmacodynamics of HER2 degradation in
response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701–6.
38. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early
tumor response to Hsp90 therapy using HER2 PET: comparison
with 18F-FDG PET. J Nucl Med 2006;47:793–6.
39. Wild D, Maecke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al.
68Ga-DOTANOC: a first compound for PET imaging with high
affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl
Med Mol Imaging 2004;32:724.
40. Decristoforo C, von Guggenberg E, Haubner R, Rupprich M,
Schwarz S, Virgolini I. Radiolabeling of DOTA-derivatised
peptides with 68Ga via a direct approach—optimization and
routine clinical application. Nuklearmedizin 2005;44:A191–2.
41. Hofmann M, Oei M, Boerner AR, Maecke H, Geworski L,
Knapp WH, et al. Comparison of Ga-68-DOTATOC and Ga-
68-DOTANOC for radiopeptide PET. Nuklearmedizin 2005;44:
A58.
42. Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester
HJ, et al. Internalization of sst2, sst3, and sst5 receptors: effects of
somatostatin agonists and antagonists. J Nucl Med 2006;47:
502–11.
43. Smith SV. Molecular imaging with copper-64. J Inorg Biochem
2004;98:1874–901.
44. Rossin R, Pan D, Qi K, Turner JL, Sun X, Wooley KL, et al.
64Cu-labeled folate-conjugated shell cross-linked nanoparticles for
tumor imaging and radiotherapy: synthesis, radiolabeling, and
biologic evaluation. J Nucl Med 2005;46:1210–8.
45. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold
AL, et al. Comparative in vivo stability of copper-64-labeled
cross-bridged and conventional tetraazamacrocyclic complexes.
J Med Chem 2004;47:1465–74.
Eur J Nucl Med Mol Imaging (2007) 34:982–993 993
